Honored at the White House Privo Technologies receives the 2016 National Tibbetts Award

Privo Technologies is pleased to announce that the company has won the 2016 National Tibbetts award for outstanding contributions to the Small Business Innovation Research (SBIR) program. The SBIR program stated “We are proud to recognize your company’s outstanding work that has contributed so greatly to the success of the SBIR program.” Privo would like to congratulate it’s team for their hard work and dedication to the company. On January 10, 2017, Privo’s CEO and Founder, Dr. Manijeh Goldberg, received the honor at the White House during a special awards ceremony.

Go to article
January 10, 2017

Share this post

Author

Related Posts

01Jan

Our Oral Cancer treatment receives MIT’s Innovation Award two years in a row.

The project was awarded over $300,000 in funding from MIT’s Deshpande Innovation Center in 2012 and 2013 to support the... read more

30Jun

Privo Technologies Announces the Appointment of Dr. James Mackay to Its Board of Directors

Privo Technologies (Privo), a Leader in the Field of Novel, Nanotechnology-Based Localized Oncology Treatments, is Pleased to Announce the Appointment... read more

04Feb

Privo Technologies, Inc. To Present at the 24th Annual BIO CEO & Investor Conference

Peabody, MA– Privo Technologies, Inc. (“Privo”), a clinical-stage biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough on cancer,... read more

19Aug

Privo Technologies Named Winner of AIM-HI Accelerator Fund’s Inaugural Women’s Venture Competition 2020

PEABODY, Mass., Sept. 24, 2020 -- Privo Technologies, Inc. ("Privo"), a biopharmaceutical company focused on breakthrough localized treatments for tough to treat mucosal... read more

10Dec

Privo Technologies Opens New Lab Facility in Peabody, MA

Privo Technologies expands to a new 3,000 square foot facility just outside of Boston, MA. Located at 200 Corporate Place,... read more

06Jun

BIO International Convention

Privo Technologies attends BIO International Convention as an invited guest of the National Institute of Dental and Craniofacial Research Institute... read more

01Mar

Privo receives a $2M Award from the National Institute of Dental and Craniofacial Research (NIDCR)

Privo Technologies is honored to receive a Phase 2 award for $2M from the NIDCR SBIR program to further develop its scale-up, chemistry, and manufacturing program. read more

19Aug

Privo Technologies, Inc. Presents Phase II Data for PRV111 in Head and Neck Squamous Cell Carcinoma at the 2021 ASCO Annual Meeting

PEABODY, Mass., June 3, 2021  -- Privo Technologies, Inc. (“Privo”), a biopharmaceutical company focused on optimizing state-of-the-art chemotherapies to be “Tough... read more

17Apr

Privo Technology’s CEO, Manijeh Goldberg, speaks at IDEASTREAM, MIT Deshpande Center Symposium.

Watch Dr. Goldberg's presentation below regarding localized treatment of cancers in a more safe and effective way and the positive... read more

03Nov

Privo receives Orphan Designation from the Food and Drug Administration.

Privo Technologies received Orphan Designation for anatomically accessible oral cancers. Receipt of this designation entitles Privo’s current and future oral... read more

Contact Us
close slider

Contact Us